Pieris Pharmaceuticals, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 15.57 million compared to USD 5.11 million a year ago. Revenue was USD 19.52 million compared to USD 5.37 million a year ago. Net loss was USD 10.75 million compared to USD 9.74 million a year ago. Basic loss per share from continuing operations was USD 8.8 compared to USD 10.4 a year ago.
For the nine months, sales was USD 37.67 million compared to USD 19.76 million a year ago. Revenue was USD 41.51 million compared to USD 20.06 million a year ago. Net loss was USD 19.96 million compared to USD 25.18 million a year ago. Basic loss per share from continuing operations was USD 18.4 compared to USD 27.2 a year ago.